Skip to Content

'
Naval G. Daver, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 425
Houston, TX 77030
Phone: 713 - 794-4392
Fax: 713-792-9616

Education & Training

Degree-Granting Education

2004 Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, India, MD, MD
1998 D.G. Ruparel College, Mumbai, India, BA, BA

Postgraduate Training

7/2008-7/2011 Clinical Fellowship, Fellowship Oncology - Hematology, Baylor College of Medicine, Houston, TX
7/2005-7/2008 Clinical Residency, Internal Medicine Residency, Baylor College of Medicine, Houston, TX
9/2004-6/2005 Research Fellowship, Research Assistant, Baylor College of Medicine, Houston, TX

Board Certifications

12/2011 American Board of Oncology
12/2011 American Board of Hematology
12/2008 American Board of Internal Medicine

Professional Memberships

American Society of Clinical Oncology, TX
Member, 7/2008-present
American Society of Hematology
Member, 7/2008-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Daver NG, Dumlao T, Ravandi F, Pemmaraju N, Nazha A, Pierce S, Borthakur G, Faderl S, Garcia-Manero G, Cortes, J, Kantarjian H, Quintas-Cardama A. Impact of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients with Acute Myeloid leukemia Receiving Standard Chemotherapy. Clinical Lymphoma, Myeloma & Leukemia. In Press.
2. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver NG, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 3/2013. e-Pub 1/2013. PMID: 23345254.
3. Daver NG, O'Brien S. Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia - A Focus on Emerging Monoclonal Antibodies. Curr Hematol Malig Rep. e-Pub 3/2013. PMID: 23539383.
4. Borthakur G, Rosenblum MG, Talpaz M, Daver NG, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 Study of Anti-CD33 Immunotoxin HUM-195/rGEL in Patients with Advanced Myeloid Malignancies. Haematologica 98(2):217-21, 2/2013. e-Pub 8/2012. PMCID: PMC3561428.
5. Daver NG, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: Are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk 13(1):86-9, 2/2013. e-Pub 9/2012. PMID: 22981963.
6. Daver NG, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 1/2013. e-Pub 10/2012. PMID: 23115106.
7. Lee HJ, Daver NG, Kantarjian HM, Verstovsek S, Ravandi F. The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin Cancer Res 19(2):327-35, 1/2013. e-Pub 12/2012. PMID: 23209034.
8. Nazha A, Cortes J, Faderl S, Pierce S, Daver NG, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 8/2012. e-Pub 4/2012. PMCID: PMC3409823.
9. Tanaka MF, Daver NG,Rice L. Romiplostim: Therapeutic Value in Chronic Immune Thrombocytopenic Purpura. Clinical Medical Insights: Therapeutics(2):499-511, 5/2010.
10. Livorsi DJ, Daver NG , Atmar RL, Shelburne SA, White AC, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. The Journal of Infection 57(2):128-31, 8/2008. e-Pub 6/2008. PMID: 18562009.
11. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. The Journal of Infection 54(6):539-44, 6/2007. e-Pub 1/2007. PMID: 17198732.
12. del la Garza Y, Graviss EA, Daver NG, Gambarin KJ, Shandera WX, Schantz PM, White AC. Epidemiology of neurocysticercosis in Houston, Texas. American Journal Tropical Medicine and Hygiene 73(4):766-70, 10/2005. PMID: 16222023.
13. Daver GB, Bakhshi GD, Patil A, Ellur S, Jain M, Daver NG,. Bifid liver in patients with diaphragmatic hernia. Indian J Gastroenterol 24(1):27-8, 1/2005.
14. Joshi SR, Butala N, Patwardhan MR, Daver NG, Kelkar D. Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. J Assoc Physicians India 52(1):597- 598, 7/2004. PMID: 15645995.
15. Daver NG , Vega-Ruiz A, Kantrajian H, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia - Manero G, Cortes JE. A phase II Open-label Study of the Intravenous Administration of Homoharringtonine in the treatment of Myelodysplastic syndrome. International Journal of Hematology. Submitted.
16. Shastri A, Daver NG, Hayes T. A rare case of Gastric Chorio - adenocarcinoma. Rare tumors 2011. Submitted.
17. Bhamidipati P, Jabbour E, Konoplev S, Estrov Z, Cortes JE, Daver NG. EBV Induced CD30 Positive Diffuse Large B-Cell Lymphoma in a Mixed Phenotypic Leukemia patient treated with Clofarabine. Clinical Lymphoma, Myeloma & Leukemia. Submitted.
18. Chen Y, Kantarjian H, Pierce S, Faderl S, O' Brien S, Qian W, Abruzzo L, De Lima M, Kebriaaei P, Jabbour E, Daver NG, Kadia T, Garcia-Manero G, Cortes JE, Ravandi F. Prognostic Significance of 11q23 Cytogenetic Abnormalities in Adult Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation. Blood. Submitted.

Invited Articles

1. Daver N, Cortes J. Molecular targeted therapy in Acute Myeloid Leukemia. Hematology 17 Suppl 1:S59-62, 4/2012. PMID: 22507781.

Abstracts

1. Kadia T, Cortes J, Thomas D, Ravandi F, Pemmaraju N, Daver NG, Quintás-Cardama A, Baccus M, Garris R, Jabbour E, Kantarjian H, Borthakur G. A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL). 2012 ASH Annual Meeting. Blood 120 (#4308), 11/2012.
2. Faderl S, Garcia-Manero G, Ravandi F, Cortes JE, Estrov Z, Borthakur G, O'Brien S, Kadia TM, Konopleva M, Daver NG, Brandt M, Schroeder H, Kantarjian H M. A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily x 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 120 (#3851), 11/2012.
3. Pemmaraju N, Thomas D, Kantarjian H M., Cortes J E., Manning John T., Medeiros l J., O'Brien S, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Jabbour E, Faderl S. Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. 2012 ASH Annual Meeting. Blood 120, 11/2012.
4. Strati P, Kantarjian H, Cortes J E., Ravandi F, Pemmaraju N, Garcia-Manero G, Kadia T M., Jabbour E J., Nazha A, Borthakur G, Faderl S, Quintás-Cardama A, Daver NG. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. 2012 ASH Annual Meeting. Blood 120 (#1488), 11/2012.
5. Nazha A, Ravandi F, Kantarjian H, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). 2012 ASH Annual Meeting. Blood 120 (#43), 11/2012.
6. Kazmi S, Kantarjian H M., Tran K, Cortes J E., Ravandi F, Borthakur G, Jabbour E, Faderl S, Garcia-Manero G, Kadia T M., Daver NG, Pierce S, Nazha A, Quintas-Cardama A, Pemmaraju N. Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120 (#2587), 11/2012.
7. Daver NG, Kantarjian H, Garcia-Manero G, Estrov Z, Konopleva M, Burger J, O'Brien S, Ferrajoli A, Verstovsek S, Kadia T, Jabbour E, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce S, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. 2012 ASH Annual Meeting. Blood 120 (#3619), 11/2012.
8. Alattar M, Kantarjian H, Cortes J E., Kadia T, Borthakur G, Ohanian, M, Ravandi F, Garcia-Manero G, Quintas-Cardamas A, Jabbour E, Daver NG, Pierce S, Brandt M, Faderl S, Pemmaraju N. Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).2012 ASH Annual Meeting. Blood 120 (#1456), 11/2012.
9. Ravandi F, Patel K P., Luthra R, Pierce S, Borthakur G, Jabbour E J., Kadia T M., Pemmaraju N, Daver NG, Konopleva M, Faderl S, Garcia-Manero G, Cortes J E., Kantarjian H M. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).2012 ASH Annual Meeting. Blood 120 (#2483), 11/2012.
10. Jain P, Kantarjian H M., Faderl S, Patel K P., Garcia Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T M., Daver NG, Nazha A, Luthra R, Pierce S, Cortes J E., Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120 (#2484), 11/2012.
11. Jabbour E, Daver NG , Dong T (Xiao Qin) , Kadia T, O'Brien S, Cortes J E., Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian H, Garcia-Manero G. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. 2012 ASH Annual Meeting. Blood 120 (#2824), 11/2012.
12. Nazha A, Kantarjian H M., Cortes J E., Faderl S, Pierce S, Daver NG, Pemmaraju N, Ravandi F, Borthakur G, Kadia T M., Quintas-Cardama A, Garcia-Manero G. Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy. 2012 ASH Annual Meeting. Blood 120 (#4928), 11/2012.
13. Ghanem H, Garcia Manero G, Faderl S, Takahashi K, Ravandi F, Cortes J E., O'Brien S, Daver NG, Katragadda L, Pemmaraju N, Pierce S, Quintás-Cardama A, Kadia T, Kantarjian H M., JabbourE J. Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure.2012 ASH Annual Meeting. Blood 120 (#1722), 11/2012.
14. Jain P, Kantarjian H , Thomas D A., Ravandi F, Kadia T M., Burger J A., Borthakur G, Cortes J E. Daver, NG , Jabbour E J., Koller C A. Konopleva M , Pemmaraju N, Kelly M A. Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). 2012 ASH Annual Meeting. Blood 120 (#1501), 11/2012.
15. Ghanem H, Kantarjian H M., Faderl S, Jabbour E, Daver NG, Pierce S, Brandt M, Quintás-Cardama A, Luthra R, Garcia-Manero G, Cortes J E., Ravandi F. Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO). 2012 Annual Meeting. Blood 120 (#2623), 11/2012.
16. Takahashi K, Pemmaraju N, Beran M, Quintás-Cardama A, Cortes J E., Ravandi F, Faderl S, Verstovsek S, Kadia T M., Borthakur G, Jabbour E J., Daver NG, Estrov Z, Pierce S, Garcia-Manero G. Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). 2012 ASH Annual Meeting. Blood 120 (#3797), 11/2012.
17. Daver NG, Kantarjian H M., Garcia-Manero G, Cortes J E., Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T M., Burger J A., Konopleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120 (#3629), 11/2012.
18. Mathisen M, Kantarjian H, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, O'Brien S, Quintas-Cardama A, Ghanem H, Daver NG, Pierce S, Lira C, Faderl S, Jabbour E. Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). 2012 ASH Annual Meeting. Blood 120 (#3610), 11/2012.
19. Quintás-Cardama A, Kantarjian H M., Ravandi F, Foudray C, Pemmaraju N , Kadia T M. Borthakur G, Daver NG, Faderl S, Jabbour E, Cortes J E., Garcia-Manero G. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. 2012 ASH Annual Meeting. Blood 120 (#3821), 11/2012.
20. Daver NG, De Lima M, Kantarjian H, Ravandi F, Bilen M, Pierce S, Khouri I, Dorkhom S, Giralt S, Garcia-Manero G, Nazha A, Mathisen M, Pemmaraju N, Cortes JE, Faderl S, Jabbour E. Allogeneic stem cell transplant as initial salvage for patients with acute myeloid leukemia(AML) refractory to high-dose cytarabine-based induction chemotherapy. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15) (#6544), 5/2012.
21. Pemmaraju N, Thomas DA, Kantarjian H, O'Brien S, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Cortes JE, Faderl S. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15) (#6578), 5/2012.
22. Bhamidipati P, Daver NG, Kantarjian H, Pierce S, Daver R, Cortes JE, Ravandi F, Mathisen M, Pemmaraju N, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Garcia-Manero G. FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15) (#6597), 5/2012.
23. Mathisen M, Kantarjian H, Faderl S, Garcia-Manero G, Ravandi F, Kadia T, Daver NG, O'Brien S, Dorkhom S, Pierce S, Lira C, Cortes JE, Jabbour E. Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15) (#6607), 5/2012.
24. Kadia T, Jabbour E, Pemmaraju N, Faderl S, Borthakur G, Thomas DA, Daver NG, Ravandi F, Kantarjian H. Phase II Study of Omacetaxine (OM) & Low Dose AraC (LDAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15) (#6592), 5/2012.
25. Alattar M, Kantarjian H, Burger J, Richie M, Garcia-Manero G, Konopleva M, Faderl S, Borthakur G, Daver NG, Kadia T, Cortes JE, Ravandi F. Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15) (#6558), 5/2012.
26. Daver NG, Kantarjian H, Garcia-Manero G, Borthakur G, Ravandi F, Kadia T, Estrov Z, Konopleva M, Faderl S, Cortes JE. AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood 118 (#3820), 11/2011.
27. Garcia-Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda W, Estrov Z, Faderl S, Kadia T, Rey K, Cheung C, Kantarjian H. Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood 118 (#2613), 11/2011.
28. Nazha A, Bhatt VR, Nogueras-Gonzalez G, Kadia T, Cortes JE, Daver NG, Garcia-Manero G, Kantarjian H, Borthakur G. Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. Blood 118 (#1495), 11/2011.
29. Daver NG, Kantarjian H, Garcia - Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination is Effective in Patients with Relapsed / Refractory Acute Myeloid Leukemia, High - Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood 118 (#3629), 11/2011.

Book Chapters

1. Daver NG, Udden M. Acute Lymphoblastic Leukemia. In: Hematology Oncology. In Press.

Grant & Contract Support

Title: 2012-0737: Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients with Myelofibrosis and Myelodysplastic/ Myeloproliferative Neoplasms
Funding Source: InCyte
Role: Principal Investigator-MDACC
Duration: 2/5/2013 - 2/4/2016

Last updated: 8/21/2013